anti-TFR1 monoclonal antibody

An anti-TFR1 monoclonal antibody is a therapeutic agent designed to target transferrin receptor 1 (TFR1, also known as CD71), a type II transmembrane glycoprotein that plays a critical role in cellular iron uptake by binding and internalizing iron-bound transferrin. TFR1 is highly expressed on rapidly proliferating cells, including various cancer cells and erythroid progenitor cells, making it an attractive target for oncology and hematological disorders. In addition, recent research has implicated TFR1 in the pathogenesis of respiratory diseases such as asthma, where TFR1-mediated iron accumulation in airway macrophages drives inflammation, airway hyper-responsiveness, and tissue remodeling. Anti-TFR1 monoclonal antibodies can act through neutralizing mechanisms (blocking transferrin binding and iron uptake) or non-neutralizing mechanisms (inducing receptor internalization and degradation, or mediating antibody-dependent cellular cytotoxicity). Several anti-TFR1 antibodies, such as PPMX-T003, are in clinical or preclinical development for hematological malignancies, polycythemia vera, and respiratory conditions.

Other names

anti-TFR1 antibodyanti-TFR-1 antibodyanti-TFR 1 antibodyanti-TfR1 monoclonal antibodyanti-TfR-1 monoclonal antibodyanti-TfR 1 monoclonal antibodyanti-transferrin receptor 1 antibodyanti-transferrin receptor 1 monoclonal antibodyαTFR1